An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies

Trial Profile

An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs BAY 1143572 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 22 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 05 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Nov 2016.
    • 05 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top